Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) EBITDA Margin (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed EBITDA Margin for 3 consecutive years, with 188.49% as the latest value for Q1 2025.

  • Quarterly EBITDA Margin changed N/A to 188.49% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 1326.87% through Dec 2025, changed N/A year-over-year, with the annual reading at 1326.87% for FY2025, N/A changed from the prior year.
  • EBITDA Margin for Q1 2025 was 188.49% at Centessa Pharmaceuticals, down from 1405.56% in the prior quarter.
  • The five-year high for EBITDA Margin was 3979.73% in Q2 2022, with the low at 188.49% in Q1 2025.
  • Average EBITDA Margin over 3 years is 2029.36%, with a median of 1950.75% recorded in 2022.
  • Peak annual rise in EBITDA Margin hit -54518bps in 2023, while the deepest fall reached -302704bps in 2023.
  • Over 3 years, EBITDA Margin stood at 1950.75% in 2022, then decreased by -28bps to 1405.56% in 2023, then tumbled by -113bps to 188.49% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 188.49%, 1405.56%, and 1527.55% for Q1 2025, Q4 2023, and Q3 2023 respectively.